Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death

  • Bayer AG BAYRY reported disappointing results from its approved med Kerendia (finerenone) didn’t reach significance on all-cause mortality in a pooled analysis of two Phase 3 trials of the drug.
  • Last July, the FDA approved the drug to slow chronic kidney disease progression in patients with CKD associated with type 2 diabetes. 
  • In a pooled analysis of the company’s Phase 3 FIDELIO-DKD and FIGARO-DKD studies, Kerendia did not reach statistical significance on all-cause or cardiovascular mortality. 
  • Bayer said the drug “narrowly missed” that mark and that an on-treatment analysis provided a more favorable picture.
  • Related: Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials.
  • Finerenone was found to reduce sudden cardiac death vs. placebo significantly.
  • All-cause mortality rates were 8.5% in the Kerendia-treated group and 9.4% in the placebo.
  • Bayer said CV mortality made up the most common cause of death in the trial, comprising 4.9% of the Kerendia group and 5.6% of the placebo group.
  • Price Action: BAYRY shares are down 3.82% at $12.83 on the last check Monday.
Posted In: BiotechLarge CapNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!